Literature DB >> 19737537

Identification and characterization of novel TRPV4 modulators.

Fabien Vincent1, Alejandra Acevedo, Margaret T Nguyen, Michelle Dourado, Jeff DeFalco, Amy Gustafson, Peter Spiro, Daniel E Emerling, Michael G Kelly, Matthew A J Duncton.   

Abstract

TRPV4, a close relative of the vanilloid receptor TRPV1, is activated by diverse modalities such as endogenous lipid ligands, hypotonicity, protein kinases and, possibly, mechanical inputs. While its multiple roles in vivo are being explored with KO mice and selective agonists, there is a dearth of selective antagonists available to examine TRPV4 function. Herein we detail the use of a focused library of commercial compounds in order to identify RN-1747 and RN-1734, a pair of structurally related small molecules endowed with TRPV4 agonist and antagonist properties, respectively. Their activities against human, rat and mouse TRPV4 were characterized using electrophysiology and intracellular calcium influx. Significantly, antagonist RN-1734 was observed to completely inhibit both ligand- and hypotonicity-activated TRPV4. In addition, RN-1734 was found to be selective for TRPV4 in a TRP selectivity panel including TRPV1, TRPV3 and TRPM8, and could thus be a valuable pharmacological probe for TRPV4 studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19737537     DOI: 10.1016/j.bbrc.2009.09.007

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  85 in total

1.  TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice.

Authors:  Shaik O Rahaman; Lisa M Grove; Sailaja Paruchuri; Brian D Southern; Susamma Abraham; Kathryn A Niese; Rachel G Scheraga; Sudakshina Ghosh; Charles K Thodeti; David X Zhang; Magdalene M Moran; William P Schilling; Daniel J Tschumperlin; Mitchell A Olman
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Activation of endothelial TRPV4 channels mediates flow-induced dilation in human coronary arterioles: role of Ca2+ entry and mitochondrial ROS signaling.

Authors:  Aaron H Bubolz; Suelhem A Mendoza; Xiaodong Zheng; Natalya S Zinkevich; Rongshan Li; David D Gutterman; David X Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

Review 3.  Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.

Authors:  Peter Holzer
Journal:  Pharmacol Ther       Date:  2011-03-21       Impact factor: 12.310

Review 4.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

5.  Pregnancy-induced remodelling and enhanced endothelium-derived hyperpolarization-type vasodilator activity in rat uterine radial artery: transient receptor potential vanilloid type 4 channels, caveolae and myoendothelial gap junctions.

Authors:  Sevvandi Senadheera; Paul P Bertrand; T Hilton Grayson; Leo Leader; Timothy V Murphy; Shaun L Sandow
Journal:  J Anat       Date:  2013-10-16       Impact factor: 2.610

6.  Prevention of ventilator-induced lung edema by inhalation of nanoparticles releasing ruthenium red.

Authors:  Samuel C Jurek; Mariko Hirano-Kobayashi; Homer Chiang; Daniel S Kohane; Benjamin D Matthews
Journal:  Am J Respir Cell Mol Biol       Date:  2014-06       Impact factor: 6.914

7.  17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception.

Authors:  S Bang; S Yoo; T J Yang; H Cho; S W Hwang
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 8.  Deciphering physiological role of the mechanosensitive TRPV4 channel in the distal nephron.

Authors:  M Mamenko; O Zaika; N Boukelmoune; R G O'Neil; O Pochynyuk
Journal:  Am J Physiol Renal Physiol       Date:  2014-12-10

9.  The tyrosine kinase inhibitor bafetinib inhibits PAR2-induced activation of TRPV4 channels in vitro and pain in vivo.

Authors:  M S Grace; T Lieu; B Darby; F C Abogadie; N Veldhuis; N W Bunnett; P McIntyre
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

10.  TRPV4 as a target for bladder overactivity.

Authors:  Patrizia Angelico; Rodolfo Testa
Journal:  F1000 Biol Rep       Date:  2010-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.